| Enrolling By Invitation | Vaginal Ecosystem and Network in the United States Study NCT06472765 | Vaginal Biome Science | — |
| Completed | Prospective Observational Study on the Incidence of Opportunistic Fungal Infections NCT05707156 | University of Colorado, Denver | — |
| Completed | The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis NCT05235711 | Mayo Clinic | — |
| Completed | Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women NCT05044156 | Usak State Hospital | — |
| Unknown | Bioavailability of Flucanazole NCT04502277 | Sutphin Drugs | EARLY_Phase 1 |
| Completed | Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Admin NCT04122560 | Radboud University Medical Center | Phase 4 |
| Recruiting | PTX3-targeted Antifungal Prophylaxis NCT03828773 | Bochud Pierre-Yves | N/A |
| Completed | Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections NCT02860845 | Laboratorios Ordesa | Phase 4 |
| Completed | Validity of Patient-Collected Wet Mounts NCT02641717 | The University of Texas Health Science Center at San Antonio | N/A |
| Completed | A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers NCT02493738 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients NCT02666716 | Radboud University Medical Center | — |
| Completed | Fluconazole Versus Micafungin in Neonates With Candidiasis NCT02145832 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 2 / Phase 3 |
| Completed | Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses an NCT03203551 | University of Sao Paulo | N/A |
| Completed | Candida Host Defense Response After Septic Shock in the Critically Ill NCT03136081 | University Hospital, Montpellier | — |
| Terminated | Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Can NCT02646800 | Astellas Pharma China, Inc. | Phase 4 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia NCT01982071 | Astellas Pharma China, Inc. | Phase 4 |
| Completed | Effect of Probiotic Bacteria on Oral Candida in Frail Elderly NCT02391532 | University of Copenhagen | N/A |
| Completed | Immunological Interaction Between the Host and Candida Albicans Biofilm NCT01919931 | Universitaire Ziekenhuizen KU Leuven | — |
| Terminated | Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of NCT00815516 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Completed | Staging Candidiasis in ICU Patients NCT01322698 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine NCT01447407 | NovaDigm Therapeutics, Inc. | Phase 1 |
| Completed | Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in NCT01230814 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom NCT01202253 | Pfizer | — |
| Completed | Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida NCT01273922 | NovaDigm Therapeutics, Inc. | Phase 1 |
| Terminated | A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infecti NCT01092832 | Pfizer | Phase 3 |
| Completed | Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections NCT01102387 | Almirall, S.A. | Phase 2 |
| Unknown | Pre-hospital Risk Factors for Invasive Fungal Infection NCT01315925 | Catholic University of the Sacred Heart | — |
| Unknown | A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China NCT01253954 | Southeast University, China | — |
| Unknown | Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of M NCT00889356 | Zodiac Produtos Farmaceuticos S.A. | Phase 3 |
| Terminated | An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Se NCT00806351 | Pfizer | Phase 3 |
| Terminated | An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of De NCT00805740 | Pfizer | Phase 3 |
| Completed | Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk Fo NCT00739934 | Pfizer | Phase 2 |
| Completed | Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers NCT00797420 | Daniel Benjamin | Phase 1 |
| Completed | Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight NCT00734539 | Daniel Benjamin | Phase 3 |
| Terminated | Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility NCT00692783 | University of Florida | — |
| Completed | A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and NCT00784368 | Janssen Pharmaceutical K.K. | Phase 3 |
| Completed | Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidias NCT00496197 | Pfizer | Phase 4 |
| Completed | Novel Rinse to Treat in Oral Candidiasis in Cancer Patients NCT00612963 | Biomedical Development Corporation | — |
| Withdrawn | Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients NCT00304772 | Kyoto University | Phase 4 |
| Completed | Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058) NCT00330395 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units NCT00099775 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Caspofungin Study for Fungal Infections in Adults in Critical Care Settings NCT00095316 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Study of Micafungin in Patients With Invasive Candidiasis or Candidemia NCT00105144 | Astellas Pharma Inc | Phase 3 |
| Completed | Caspofungin for the Treatment of Non-blood Candida Infections (0991-045) NCT00083343 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043) NCT00082524 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Early Diagnosis of Candidiasis in Premature Infants NCT00109525 | NICHD Neonatal Research Network | — |
| Completed | Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection NCT00388167 | PETHEMA Foundation | — |
| Completed | Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments NCT00313131 | Université de Sherbrooke | Phase 3 |
| Completed | A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections NCT00647907 | Pfizer | Phase 4 |
| Completed | Anidulafungin Versus Fluconazole in the Treatment of Candidemia NCT00058682 | National Cancer Institute (NCI) | Phase 3 |
| Completed | The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasi NCT00056368 | Pfizer | Phase 3 |
| Completed | Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia NCT00106288 | Astellas Pharma Inc | Phase 3 |
| Completed | The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis ( NCT00041704 | Pfizer | Phase 2 |
| Completed | Funguria in Hospitalized Patients NCT00138502 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasi NCT00037219 | Pfizer | Phase 2 |
| Completed | Voriconazole to Prevent Systemic Fungal Infections in Children NCT00005912 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone NCT00001937 | National Cancer Institute (NCI) | Phase 3 |
| Completed | An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voricon NCT00001810 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis NCT00036179 | Astellas Pharma Inc | Phase 2 |
| Completed | A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fl NCT00163111 | Pfizer | Phase 3 |
| Completed | Fluconazole Prophylaxis of Thrush in AIDS NCT00001542 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Completed | Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventio NCT00002038 | Pfizer | N/A |
| Completed | A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of NCT00000788 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal In NCT00000676 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transpl NCT00001107 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Completed | A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Pro NCT00000744 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |